BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31839394)

  • 1. Association between body mass index and oocyte maturation in patients triggered with GnRH agonist who are at high risk for severe ovarian hyperstimulation syndrome: an observational cohort study.
    Lainas GT; Lainas TG; Sfontouris IA; Venetis CA; Bosdou JK; Chatzimeletiou A; Grimbizis GF; Tarlatzis BC; Kolibianakis EM
    Reprod Biomed Online; 2020 Jan; 40(1):168-175. PubMed ID: 31839394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
    Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
    Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
    J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
    Itskovitz-Eldor J; Kol S; Mannaerts B
    Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
    Griesinger G; Diedrich K; Devroey P; Kolibianakis EM
    Hum Reprod Update; 2006; 12(2):159-68. PubMed ID: 16254001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of human chorionic gonadotropin (Pregnyl 10 000 IU i.m.) versus GnRH agonist (triptorelin 0,2 mg s.c.) for final oocytes maturation in the same egg donors--clinical and embryological characteristics].
    Streda R; Mardesic T; Sobotka V; Koryntová D; Hybnerová L; Jindra M; Paseková V; Slámová J; Stevíková M; Voboril J; Jelínková L; Vilímová S; Ichová J; Mádrová J; Tersová H; Masata M; Sobotková J
    Ceska Gynekol; 2011 Apr; 76(2):113-8. PubMed ID: 21649994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation.
    Popovic-Todorovic B; Santos-Ribeiro S; Drakopoulos P; De Vos M; Racca A; Mackens S; Thorrez Y; Verheyen G; Tournaye H; Quintero L; Blockeel C
    Hum Reprod; 2019 Oct; 34(10):2027-2035. PubMed ID: 31560740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
    O'Neill KE; Senapati S; Maina I; Gracia C; Dokras A
    J Assist Reprod Genet; 2016 Sep; 33(9):1175-84. PubMed ID: 27349252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.
    Griesinger G; von Otte S; Schroer A; Ludwig AK; Diedrich K; Al-Hasani S; Schultze-Mosgau A
    Hum Reprod; 2007 May; 22(5):1348-52. PubMed ID: 17303632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
    Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
    Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
    Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
    Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.
    Abbara A; Jayasena CN; Christopoulos G; Narayanaswamy S; Izzi-Engbeaya C; Nijher GM; Comninos AN; Peters D; Buckley A; Ratnasabapathy R; Prague JK; Salim R; Lavery SA; Bloom SR; Szigeti M; Ashby DA; Trew GH; Dhillo WS
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3322-31. PubMed ID: 26192876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols.
    Orvieto R; Rabinson J; Meltzer S; Zohav E; Anteby E; Homburg R
    Reprod Biomed Online; 2006 Aug; 13(2):198-201. PubMed ID: 16895632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
    Atkinson P; Koch J; Ledger WL
    Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.